Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002045106 | SCV002296284 | uncertain significance | Alpha-methylacyl-CoA racemase deficiency | 2022-03-12 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with AMACR-related conditions. This variant is present in population databases (rs769044213, gnomAD 0.03%). This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 36 of the AMACR protein (p.Arg36Trp). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004641877 | SCV005130038 | uncertain significance | Inborn genetic diseases | 2024-06-11 | criteria provided, single submitter | clinical testing | The c.106C>T (p.R36W) alteration is located in exon 1 (coding exon 1) of the AMACR gene. This alteration results from a C to T substitution at nucleotide position 106, causing the arginine (R) at amino acid position 36 to be replaced by a tryptophan (W). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |